Benefits
Blood Sugar Regulation
Berberine may improve insulin sensitivity and lower blood glucose levels, potentially aiding in type 2 diabetes management. Studies suggest it activates AMPK, a pathway that regulates metabolism.
Cardiovascular Health
It can reduce cholesterol levels (LDL and triglycerides) and improve heart health by supporting healthy blood pressure and reducing inflammation.
Weight Management
Some evidence indicates berberine may promote weight loss by enhancing fat metabolism and reducing appetite, though results vary.
Gut Health
Berberine has antimicrobial properties, which may help balance gut microbiota, reduce harmful bacteria, and alleviate digestive issues like diarrhea.
Anti-inflammatory and Antioxidant Effects
It may reduce inflammation and oxidative stress, potentially benefiting conditions like arthritis or chronic diseases.
Potential Anticancer Properties
Preliminary studies suggest berberine may inhibit cancer cell growth, but more research is needed.
Mechanism of action
Activation of AMPK (AMP-activated Protein Kinase)
Berberine activates AMPK, a key regulator of energy metabolism, often called a "metabolic master switch." This increases glucose uptake in cells, enhances insulin sensitivity, and promotes fatty acid oxidation, contributing to improved blood sugar control and lipid metabolism.
Inhibition of Mitochondrial Function
Berberine inhibits complex I of the mitochondrial respiratory chain, reducing ATP production. This triggers AMPK activation indirectly and may contribute to its metabolic effects.
Antimicrobial Activity
Berberine disrupts bacterial cell membranes and inhibits DNA replication in microbes, helping to combat harmful gut bacteria and pathogens, which supports gut health.
Regulation of Gene Expression
It modulates transcription factors like PPARs (peroxisome proliferator-activated receptors) and inhibits pro-inflammatory pathways (e.g., NF-κB), reducing inflammation and oxidative stress.
Inhibition of Enzymes
Berberine inhibits enzymes like PCSK9, reducing LDL cholesterol levels, and α-glucosidase, slowing carbohydrate absorption in the gut, aiding blood sugar control.
Gut Microbiota Modulation
It alters gut microbiota composition, promoting beneficial bacteria and reducing harmful ones, which may influence metabolism and inflammation.
Potential Anticancer Effects
Berberine may induce apoptosis (programmed cell death) and inhibit proliferation in cancer cells by affecting pathways like PI3K/Akt and MAPK, though this is still under investigation.
Clinical trials
Evidence review and pooled analysis of 16 randomized controlled trials evaluating berberine monotherapy on metabolic disorders (T2DM, dyslipidemia, hypertension). Outcomes: HbA1c, FPG, LDL, total cholesterol, BP.
Pooled across 16 clinical trials — varied populations with metabolic risk factors.
Berberine significantly reduced HbA1c (~0.7%), fasting plasma glucose (~0.7 mmol/L), total cholesterol, LDL, and triglycerides vs placebo or comparators. BP modestly reduced. Effects comparable to first-line oral antidiabetic agents in some trials. Bioavailability remains a major limitation (~5%), prompting interest in dihydroberberine and phytosomal forms.
Prospective, randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial (NCT03656744) of berberine ursodeoxycholate (HTD1801) in 100 subjects with primary sclerosing cholangitis or non-alcoholic fatty liver disease. (Nat Commun)
100 subjects with cholestatic or fatty liver disease.
HTD1801 reduced liver enzymes and improved liver-related biomarkers vs placebo. Provides proof-of-concept for the berberine ursodeoxycholate ionic salt (a co-crystal designed for improved oral bioavailability over standard berberine).
Randomized, double-blind, placebo-controlled trial in 34 individuals with prediabetes (per ADA criteria) receiving HIMABERB® berberine vs placebo. Outcomes: fasting glucose, HbA1c, lipid profile, body composition. (2023)
34 prediabetic adults.
HIMABERB® reduced fasting glucose and HbA1c trends vs placebo. Lipid improvements observed. Small sample size limits strong conclusions; supports berberine for early glycemic intervention in prediabetes.
Pooled analysis (PROSPERO) of randomized controlled trials through assessing berberine effects on NAFLD outcomes including liver enzymes, hepatic steatosis, lipid profile. (2024, J Transl Med)
Pooled across multiple clinical trials in NAFLD patients.
Berberine significantly reduced ALT, AST, total cholesterol, triglycerides, and improved hepatic steatosis vs placebo or lifestyle intervention alone. Heterogeneity in formulations and doses across studies. Authors propose berberine as adjunctive therapy for NAFLD pending larger confirmatory trials.
Randomized controlled trial in China evaluating berberine ursodeoxycholate (BUDCA) on HbA1c, glycemic control, hepatic markers, and cardiometabolic outcomes in T2DM patients. (2025, JAMA Netw Open)
T2DM patients in China.
Berberine ursodeoxycholate produced significant HbA1c reductions and improvements in lipid profile, hepatic enzymes, and select cardiometabolic markers vs control. Salt formulation appears to provide better bioavailability than conventional berberine HCl.
Randomized controlled trial in patients with schizophrenia receiving berberine (900 mg/day) for 8 weeks as adjunctive treatment to antipsychotics. Outcomes: glycolipid metabolism (FPG, lipids, insulin), weight, antipsychotic-induced metabolic side effects. (2021, Psychiatry Research)
Schizophrenia patients on antipsychotic medication. 8-week intervention.
Berberine adjunct significantly improved glycolipid metabolism markers (FPG, total cholesterol, LDL, HOMA-IR) and attenuated antipsychotic-induced metabolic side effects vs placebo. Important emerging application for managing antipsychotic metabolic syndrome.